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performed per sample for the serum, but that there is minimal
loss of the BAP analyte out to 5 freeze/thaw cycles for the SF.
Conclusions: The Metra® BAP assay is a reproducible and valid
assay for use with equine serum and synovial fluid.
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Purpose: Synovial fluid as a lubricant of knee joints has its vis-
cosity depending on the molecular weight (MW) and concentra-
tion of hyaluronan (HA). HA concentration in synovial fluid have
been frequently reported, but there are few reports analysing
MW of HA in synovial fluid of patients with osteoarthritis(OA).
The purpose of this study was to measure the MW of HA by
using SEC-LALLS (Size-exclusion chromatography(SEC)- a low-
angle laser light scattering(LALLS)) system, and to evaluate the
change in MW of HA after glucosamine administration.
Methods: Five knee OA patients(3 men, 2 women, mean age:
60.6 years) recieved 1.5g of glucosamine hydrochloride per day
for one month. Synovial fluid samples were collected before and
after glucosamine administration.The SEC-LALLS system(Asahi
Techneion) was used to determine the MW of HA. First,the HA
fraction was separated by using SEC system and then the MW of
HA was calculated by measuring LALLS and refractive index(RI).
Triple Detector Array (Viscotek Corporation)which has a LALLS
detector, a RI detector and a viscometer was utilized for the
measurement. Before analyzing HA samples, the accuracy of the
SEC-LALLS system was calibrated with three HA standards (su-
venyl, artz and HA(lowMW-type)(Seikagaku Corporation). (MW
of suvenyl, artz and low MW HA: 1900-2500, 600-1200 and
100-150(kDa)) Furthermore, hyaluronidase treatment was also
done for the confirmation of HA. As a clinical test,visual analogue
scale (VAS) of OA patients was also measured.
Results: The SEC-LALLS system was effective in the MW mea-
surement of HA. MW of three kinds of HA standards,suvenyl,
artz and HA(lowMW-type)were estimated as 2400, 870 and
160(kDa)respectively. It was succeeded that HA fraction was
isolated and identified from synovial fluid samples using this sys-
tem with high sensitivity. As a proof of HA, it was demonstrated
that this peak fraction from HA disappeared after hyaluronidase
digestion. The MW of HA (mean±SD) in synovial fluid of OA pa-
tients increased from 4350±1170 to 5030±1280(kDa) after glu-
cosamine treatment. VAS for knee pain(mean±SD) decreased
significantly from 4.8±1.3 to 1.7±1.0.
Conclusions: We could separate HA from human synovial fluid
and determine the MW of HA with high sensitivity by using
the SEC-LALLS system. A change in MW of HA was detected
after glucosamine treatment, and knee pain was also alleviated.
Therefore these changes suggested glucosamine had an effect
on the metabolism of HA. Estimating the change in MW of
HA by this system may be useful for monitoring a treatment
process of symptom modifying OA drugs. Nevertheless, further
clinical studies in a lager scale are needed to investigate the
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Purpose: The expression of chondrogenic markers (collagen
type II and X, aggrecan, cartilage oligomeric matrix protein)
are largely restricted to cartilage and play a role in cartilage
metabolism and function. Recently we have shown that (unpub-
lished) these markers are also expressed in adult rat bone and
primary osteoblasts. In this study, we sought to confirm their
expression at mRNA and protein level in bone; compare the
temporal expression of these markers to established osteogenic
markers in ovariectomized (Ovx) rat model of osteopenia; and
evaluate the regulation of these markers upon treatment with
known bone anabolic agents.
Methods: Six-month old, female Sprague Dawley rats (n=10),
were Ovx or sham-operated. The animals were sacrificed at 2,
4, 6, 8 and 12 weeks post-ovx and left femur was analyzed
for BMD and BMC using quantitative computerized tomography.
The right femur (distal metaphysis without epiphysis) was pro-
cessed for mRNA analysis of osteogenic (collagen α1 (I), α2
(I), α1 (V), osteocalcin, osteonectin, bone sialoprotein, biglycan,
alphos) and chondrogenic (collagen α1 (II), aggrecan, COMP,
Cdrap) markers by quantitative real-time PCR (qPCR). Biochem-
ical markers of bone and cartilage turnover (collagen type I and
II degradation products in the serum CTX-I and CTX-II) were
measured by ELISA. Type II collagen and aggrecan proteins
in bones were confirmed by Western analysis and LC/MS. To
assess the effects of bone anabolic agents on the regulation
of bone and cartilage markers, Ovx rats permitted to lose bone
for one month were treated with PTH (1-38) at 10 μg/kg, sc
or 603281-31-8 at 3mg/kg/d (GSK-3 inhibitor), po for 60 days.
Twenty-four hr after the last treatment, RNA from distal femur
metaphysis was analyzed by qPCR to assess the expression
levels of these marker genes. Pearson correlation coefficients
were used to measure correlations between gene expression
and phenotypic parameters
Results: qPCR confirmed the expression of the chondrogenic
markers in bone and in primary osteoblasts. LC/MS and Western
analysis validated the presence of type II collagen and aggrecan
proteins in both metaphyseal and diaphyseal bone. Ovx for 12
weeks resulted in significantly lower BMD at whole and distal
femur (10-15%) relative to sham controls. This was associated
with a temporal decrease in the expression levels of chondro-
genic markers (2 to 5-fold) with optima observed at 8-12 weeks
post-ovx. In contrast, the expression levels of osteogenic mark-
ers steadily increased with maxima observed at 6 weeks (1.2
to 4-fold) followed by decline below sham levels. The levels of
CTX-I and CTX-II were increased in the serum of Ovx rats and
returned to near sham levels by 12 weeks. The magnitude of
change in CTX-II levels (4.8-fold) was > CTX-I (1.9-fold). Treat-
ment with bone anabolics, PTH or GSK-3 inhibitor restored bone
mass in Ovx rats and was associated with a robust increase in
the gene expression of chondrogenic (1.6 to 4.7-fold) compared
to osteogenic markers (1.1 to 1.8-fold). Interestingly, overall the
chondrogenic markers showed a better correlation (r=0.71) to
BMD & BMC compared to osteogenic markers (r<0.5).
Conclusions: These results demonstrate the presence and the
regulation of chondrogenic markers in rat long bone. This sug-
gests either the continued presence of cartilage in adult rat bone
